The Mechanistic and Therapeutic Rationale for Dual SGLT1/2 Inhibition in Adults with Type 1 Diabetes

Program Medium

Internet-based program

 

Estimated Time to Complete Educational Activity

2.5 hours

 

Course Overview

In this web-based program, physicians will learn how recent developments in multimodal therapies have advanced the management of type 1 diabetes.

 

Release Date

July 30, 2018

 

Expiration Date

July 30, 2020

 

Method of Physician Participation Utilized in Learning Process

There are no fees for participating and receiving CME credit for this activity. During the period July 30, 2018 through July 30, 2020 participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity, and are expected to view all 6 segments totaling 2.5 hours to successfully complete the activity and earn CME credit; 3) register and complete the evaluation form and post-test; 4) score 100% on the post-test; and 5) print out your CME certificate.

 

Registration

CME-certified program and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.

 

Grantor Support

Supported by an educational grant from IpsenSupported by an educational grant from Sanofi US and Lexicon Pharmaceuticals 

Accreditation Statement

This activity has been planned and implemented in accordance with accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Massachusetts Medical School and CMEducation Resources, LLC. University of Massachusetts Medical School  is accredited by the ACCME to provide continuing medical education for physicians.

 

Credit Designation Statement

The University of Massachusetts Medical School designates this enduring material for a maximum of 2.5 AMA PRA Category 1 Credits(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

Policy on Faculty & Provider Disclosure

It is the policy of the University of Massachusetts Medical School to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.

 

Other Credits

American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credits™ from organizations accredited by the ACCM.

 

Program Faculty and Disclosure

Robert Henry, MD – Program Co-Chair
Chief, Center for Metabolic Research
Chief, Section of Endocrinology and Diabetes
Veterans Affairs Healthcare System
San Diego, CA
Professor of Medicine, Department of Medicine
Division of Endocrinology and Metabolism
University of California, San Diego
San Diego, CA
 
Consulting: Abbott, AstraZeneca, Boehringer Ingelheim, Elcelyx, Intarcia, Ionis, Johnson & Johnson, Jansen, Merck, Sanofi-Aventis
Grant/Research Support: AstraReal, Eli Lilly, Hitachi, Lexicon, Novo Nordisk, Viacyte
Speaker: Servier
Stock Options: Inarcia
 
 
Melanie J. Davies, CBE, MB, ChB, MD, FRCP, FRCGP
Diabetes Research Centre
Department of Health Sciences
Professor of Diabetes Medicine
University of Leicester School of Medicine
Leicester, United Kingdom
 
Consultant/Advisory Board: Speaker: Novo Nordisk, Sanofi-Aventis, Lilly, Merck Sharp & Dohme, Boehringer Ingelheim, AstraZeneca, Janssen
Grant/Research Support: Novo Nordisk, Sanofi-Aventis, Lilly, Boehringer Ingelheim, Janssen
Advisory Board: Servier
Speaker: Mitsubishi Tanabe Pharma Corp, Takeda Pharmaceuticals International Inc.
 
John B. Buse, MD, PhD – Program Co-Chair
Verne S. Caviness Distinguished Professor
Chief, Division of Endocrinology
Director, Diabetes Center
Director, NC Translational and Clinical Sciences Institute
University of North Carolina School of Medicine
Chapel Hill, NC
 
Consulting: Adocia, AstraZeneca, Dexcom, Elcelyx Therapeutics, Eli Lilly, Intarcia Therapeutics, Lexicon, Metavention, NovaTarg, Novo Nordisk, Sanofi, Senseonics, and vTv Therapeutics
Grant/Research Support: AstraZeneca, Boehringer Ingelheim, Johnson & Johnson, Lexicon, Novo Nordisk, Sanofi, Theracos and vTv Therapeutics
Advisory Board: AstraZeneca HealthCare Foundation
Stock Options: Mellitus Health and PhaseBio
 
Satish K. Garg, MD
Professor of Pediatrics
Secondary Appointment: Professor of Medicine
Director of Adult Diabetes Division
University of Colorado School of Medicine
Denver, CO
 
Nothing to disclose

 

Educational Objectives

Upon completion of this activity, participants will be able to:

  • Discuss the unmet therapeutic needs in adult patients with T1DM, and root causes for why such patients fail to meet glycemic target goals; and possible solutions for improving glycemic management and metabolic optimization that may be conferred by agents with mechanistic complementarity with insulin, including those therapies acting through dual SGLT1/2 inhibition  
  • Outline the advantages and limitations of insulin-based treatments of T1DM, including both patient and physician concerns about hypoglycemia and hyperglycemia
  • Differentiate the mechanistic and potential clinical distinctions between SGLT2 inhibitors and dual SGLT1/2 inhibitor of glucose co-transport channels in renal and GI organ beds; and better understand why dual inhibition may help optimize tolerance and/or efficacy in the setting of T1DM 
  • Explain the need to augment foundational insulin-based regimens in T1DM with antidiabetic agents with complementary mechanisms of action that have the potential to improve HA1c target goal attainment and reduce risk of hypoglycemia
  • Detail the mechanism(s) of action — including those affecting both renal- and GIbased glucose metabolism — associated with dual glucose transporter inhibitors of SGLT1 and SGLT2, and how complementary MOAs provided by dual SGLT1/2 inhibitors may confer additional benefits in patients with T1DM already taking insulin

 

Hardware and Software Requirements:

To participate in this program, viewers must have a PC or Macintosh computer that has active, ongoing internet access for the duration of the program, as well as a compatible Flash-viewer. An email address is required for registration, and a printer is required to print out the CME certificate.

 

Privacy Policy

When you participate in a CME activity offered by CMEducation Resources, we ask you for your name, degree, affiliation, street address, telephone number, fax number, and/or e-mail address (the "Information"). We use that Information in the following ways:

  • We use the Information to grade your post-test and to send you a certificate of completion of the CME activity. If we use a third-party company to grade your post-test and issue certificates of completion, we will give the Information to that company for that purpose only.
  • For each CME activity that you take, you must complete an evaluation questionnaire. That questionnaire asks if you are willing to participate in a follow-up survey. If you answer yes, we will use your name and contact information to send you the survey.
  • We may use the Information to send you information about other CME activities that CMEducation Resources is offering.
  • If our company is acquired by or merged into another company, we may make the Information available to the new owner/entity to use in the ways described above, to enable it to continue our business.
  • You should check this privacy policy periodically to see whether we have made any changes.